Our Reference Specification, for more details, pls contact us for COA,MSDS and certification:
Email & Skype: firstname.lastname@example.org Telephone:+86-29-89586682
Mobile:+86-15129568250; Whatsapp: +8615129568250
|Action and use||Salicylate; antipyretic; analgesic; anti-inflammatory.|
Aloxiprin Tablets contain Aloxiprin.
The tablets comply with the requirements stated under Tablets and with the following requirements.
Content of total salicylates
92.5 to 107.5% of the stated amount, calculated as O-acetylsalicylic acid, C9H8O4.
To 0.5 g of the powdered tablets add 5 ml of hydrochloric acid, boil, cool and filter. Wash the residue with 20 ml of water and combine the filtrate and washings. The resulting solution yields the reaction characteristic of aluminium salts and, after neutralisation with 1m sodium hydroxide, yields reaction A characteristic of salicylates, Appendix VI.
Maximum time, 5 minutes, Appendix XII A1.
To a quantity of the powdered tablets containing the equivalent of 0.6 g of total salicylates add 50 ml of dry ether and shake for 30 minutes. Filter rapidly through fluted filter paper and wash the paper with several portions of dry ether. To the combined filtrate and washings add 10 ml of 1m sodium hydroxide, swirl to mix and evaporate the ether on a water bath. Cool, adjust the pH to between 2.40 and 2.50 with 1m hydrochloric acid and dilute to 100 ml with water. To 20 ml of the resulting solution add 4 ml of iron (iii) chloride solution and dilute to 50 ml with acetate buffer pH 2.45. Allow to stand for 30 minutes, filter, if necessary, through a pair of fluted filter papers and measure the absorbance of the solution at the maximum at 530 nm, Appendix II B, using in the reference cell a solution prepared by diluting 4 ml of iron (iii) chloride solution to 50 ml with acetate buffer pH 2.45. The absorbance is not more than that obtained using 5 ml of a 0.036% w/v solution of salicylic acid diluted to 20 ml with water in place of the solution being examined and beginning at the words 'add 4 ml of iron (iii) chloride solution ...' (1.5%, calculated with reference to the content of total salicylates).
Not more than 15.0%, calculated as salicylic acid, C7H6O3, with reference to the content of total salicylates when determined by the following method. To a quantity of the finely powdered tablets containing the equivalent of 0.15 g of total salicylates add 40 ml of a 0.5% w/v solution of sodium fluoride in 0.1m hydrochloric acid and shake for 5 minutes. Allow the mixture to stand for 10 minutes, shaking at frequent intervals, extract with six 20-ml quantities of chloroform, filter the combined extracts through anhydrous sodium sulphate, wash with 30 ml of chloroform and dilute to 200 ml with chloroform. Dilute 20 ml of the solution to 100 ml with chloroform and measure the absorbance of the resulting solution at the maximum at 308 nm, Appendix II B. Calculate the content of C7H6O3 taking 293 as the value of A (1%, 1 cm) at the maximum at 308 nm.
|Assay||Weigh and finely powder 20 tablets. To a quantity of the powder containing the equivalent of 0.3 g of total salicylates add 50 ml of 1m sodium hydroxide and boil gently for 15 minutes with occasional swirling. Cool, adjust the pH of the mixture to between 2.40 and 2.50 with 1m hydrochloric acid and dilute to 500 ml with water. Filter a portion of the suspension; to 5 ml of the filtrate add 35 ml of acetate buffer pH 2.45 and 4 ml of iron (iii) chloride solution and dilute to 50 ml with water. Allow to stand for 30 minutes and measure the absorbance of the resulting solution at the maximum at 530 nm, Appendix II B, using in the reference cell a solution prepared by diluting 4 ml of iron (iii) chloride solution to 50 ml with acetate buffer pH 2.45. Calculate the content of total salicylates as O-acetylsalicylic acid, C9H8O4, from the absorbance obtained by repeating the procedure using 4 ml of a 0.05% w/v solution of salicylic acid in place of the solution being examined and beginning at the words 'add 35 ml of acetate buffer pH 2.45 ...'. Each g of salicylic acid is equivalent to 1.305 g of C9H8O4.|
The quantity of active ingredient is stated both as the amount of Aloxiprin and in terms of the equivalent amount of total salicylates calculated as O-acetylsalicylic acid, C9H8O4.
The packaging can be customized. the shipping term can be by sea, by air, and sample or small quantity can be shipped by DHL, FEDEX, EMS and TNT.
a) Free sample can be supplied.
b) Guide our clients by professional knowledge and teach them how to use our product after sales.
c) Accept SGS,BV any other third-party inspection before loading.
d) High quality best price Guaranteed.
Why do you choose Dideu Industries as your partner?
A) High quality can be guaranteed. Dideu Industries since 1975 are reputed chemical manufacturer and are Certified by ISO 9001;2015 and have GMP certification.Free sample can be arranged before shipment and SGS,BV and other third party inspection company are accepted before loading.For regular customers, we accept L/C 180 Days, D/P,D/A payment term. If there is any quality problem after goods arrive. Dideu Industries will do fully payment refund.
B) Best price can be guaranteed. As Dideu Industries are integrated pharmaceuticals and chemicals producer, the production cost can be controlled and price will be definitely more competitive than China trading companies.
C) Professional enginners from Dideu Industries will give professional usage guide and services after sales.
D)Dideu Industries work 7×24 hours and your request will be processed by our professional staff in different shift period.
Dideu Industries is one of the largest producer for general chemical, pharmaceutical, nutrition additive, natural extracts, agrochemical and Daily-Use Chemical in China and is headquartered in Shaanxi, China. The Dideu Group comprises subsidiaries and joint ventures in more than 10 countries and operates six integrated production sites and 21 other production sites in Europe, Asia, Australia, Americas and Africa.Its headquarters is located in Xi’An,China. Dideu has customers in over 200 countries and supplies products to a wide variety of industries.
At the end of 2014, the company employed more than 13000 people. In 2014, Group Dideu posted sales of 30 billion and income from operations before special items of about 7.5 billion. The company is currently expanding its international activities with a particular focus on Asia countries. Between 1990 and 2005, the company invested 5.2 billion in Asia, for example in sites near Guangxi,Yunnan, Sichuan, Shaanxi China,Mangalore in India,Bangkok, Thailand,Hanoi, Vietnam etc.
Dideu Industries Consist Of Five Industry Chains:
II)Nutrition Additive Industries
III)Daily-Use Chemical Products Industries & Agrochemicals
IV)Environmental Friendly Chemical And Chemurgy Industries
VI)General Chemical Industry
At Dideu, we redefine chemistry to make the world better - and have been doing so for 75 years. As one of the world's leading chemical company, we combine economic success with environmental protection and social responsibility.Through science and innovation we enable our customers in nearly every industry to meet the current and future needs of society.
At Dideu, we create chemistry for a sustainable future with science for a better life.Dideu is a Life Science company with a long and glorious history and core competencies in the areas of health care and agriculture. With our innovative products, we are contributing to finding solutions to some of the major challenges of our time. The growing and increasingly aging world population requires improved medical care and an adequate supply of food. Dideu is improving people's quality of life by preventing, alleviating and treating diseases. And we are helping to provide a reliable supply of high quality food, feed and plant based raw materials.We develop new molecules for use in innovative products and solutions to improve health. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms.Our goal is to achieve and sustain leadership positions in our markets, thus creating value for our customers, stockholders and employees. To this end, our strategy is designed to help solve some of the most pressing challenges facing humankind, and by doing this exceptionally well we aim to strengthen the company's earning power.
We are committed to operating sustainably and addressing our social and ethical responsibilities as a corporate citizen, while at the same time respecting the interests of all our stakeholders. Employees with a passion for innovation enjoy excellent development opportunities at Dideu.Exclusive Focus on the Life Science BusinessesFollowing the economic and legal independence of our former Material Science subgroup.Dideu has charted the course for its successful development as a Life Science company. Our Life Science businesses hold leading positions in innovation driven growth markets. Together they make up a strong, attractive and balanced portfolio that is resistant to fluctuations in demand and to potential risks.The previous structure comprising a strategic management holding company and operational subgroups has thus been replaced by an integrated organization under the umbrella of the strong Dideu brand. The company's operations are managed in three divisions Pharmaceuticals, Consumer Health and Crop Science and the Animal Health business unit.The business continues to be supported by the corporate functions, Dideu Business Services and the service company Currenta, while Technology Services is being integrated into Dideu Group, forming the Engineering and Technology function.